NVIV - InVivo Therapeutics Holdings Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.5200
-0.0700 (-4.40%)
As of 9:34AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.5900
Open1.5800
Bid1.5000 x 1300
Ask0.0000 x 1800
Day's Range1.5200 - 1.5800
52 Week Range1.0900 - 50.7000
Volume2,831
Avg. Volume160,832
Market Cap2.352M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-35.2770
Earnings DateMay 07, 2020 - May 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      InVivo Therapeutics Announces Closing of $7.0 Million Public Offering

      InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 2,545,455 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were approximately $7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics.

    • Business Wire

      InVivo Therapeutics Announces Pricing of $7.0 Million Public Offering

      InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 2,545,455 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering are expected to be approximately $7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics.

    • Business Wire

      InVivo Therapeutics Announces Reverse Stock Split

      InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-30 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on February 11, 2020, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the Company's existing trading symbol, "NVIV," at the market open on February 12, 2020. The new CUSIP number for the Company's common stock following the reverse stock split will be CUSIP 46186M 506/ISIN US46186M5067.

    • Benzinga

      The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

      Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

    • Biotech CEO found guilty of defrauding investors
      American City Business Journals

      Biotech CEO found guilty of defrauding investors

      The CEO of PixarBio Corp., a biopharma startup founded in Massachusetts, has been found guilty of defrauding hundreds of investors out of approximately $12.7 million.